Titre : Mitogen-Activated Protein Kinase 3

Mitogen-Activated Protein Kinase 3 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Terminal Repeat Sequences
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Mitogen-Activated Protein Kinase 3 : Questions médicales les plus fréquentes", "headline": "Mitogen-Activated Protein Kinase 3 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Mitogen-Activated Protein Kinase 3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-24", "dateModified": "2025-02-18", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Mitogen-Activated Protein Kinase 3" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Extracellular Signal-Regulated MAP Kinases", "url": "https://questionsmedicales.fr/mesh/D048049", "about": { "@type": "MedicalCondition", "name": "Extracellular Signal-Regulated MAP Kinases", "code": { "@type": "MedicalCode", "code": "D048049", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.563.567.249" } } }, "about": { "@type": "MedicalCondition", "name": "Mitogen-Activated Protein Kinase 3", "alternateName": "Mitogen-Activated Protein Kinase 3", "code": { "@type": "MedicalCode", "code": "D048052", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Juan Wang", "url": "https://questionsmedicales.fr/author/Juan%20Wang", "affiliation": { "@type": "Organization", "name": "Division of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, Seoul 05006, Republic of Korea." } }, { "@type": "Person", "name": "Mohammad Shafiq", "url": "https://questionsmedicales.fr/author/Mohammad%20Shafiq", "affiliation": { "@type": "Organization", "name": "From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India." } }, { "@type": "Person", "name": "Kumaravelu Jagavelu", "url": "https://questionsmedicales.fr/author/Kumaravelu%20Jagavelu", "affiliation": { "@type": "Organization", "name": "From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India." } }, { "@type": "Person", "name": "Neeraj Kumar Verma", "url": "https://questionsmedicales.fr/author/Neeraj%20Kumar%20Verma", "affiliation": { "@type": "Organization", "name": "Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India." } }, { "@type": "Person", "name": "Jimut Kanti Ghosh", "url": "https://questionsmedicales.fr/author/Jimut%20Kanti%20Ghosh", "affiliation": { "@type": "Organization", "name": "Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Enhancing the acid stability of the recombinant GH11 xylanase xynA through N-terminal substitution to facilitate its application in apple juice clarification.", "datePublished": "2024-04-24", "url": "https://questionsmedicales.fr/article/38670187", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ijbiomac.2024.131857" } }, { "@type": "ScholarlyArticle", "name": "Impact of C-terminal domains of paralogous single-stranded DNA binding proteins from Streptomyces coelicolor on their biophysical properties and biological functions.", "datePublished": "2024-04-11", "url": "https://questionsmedicales.fr/article/38614173", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ijbiomac.2024.131544" } }, { "@type": "ScholarlyArticle", "name": "Perinatal outcomes between immediate vs deferred selective termination in dichorionic twin pregnancies with fetal congenital anomalies: a French multicenter study.", "datePublished": "2024-04-02", "url": "https://questionsmedicales.fr/article/38574858", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ajogmf.2024.101363" } }, { "@type": "ScholarlyArticle", "name": "Correlation of cerebral microvascular circulation with vital signs in cerebral compression and the validity of three concepts: vasodilation, autoregulation, and terminal rise in arterial pressure.", "datePublished": "2024-03-22", "url": "https://questionsmedicales.fr/article/38628505", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.25259/SNI_998_2023" } }, { "@type": "ScholarlyArticle", "name": "BRCA1 and Its Vulnerable C-Terminal BRCT Domain: Structure, Function, Genetic Mutations and Links to Diagnosis and Treatment of Breast and Ovarian Cancer.", "datePublished": "2024-03-04", "url": "https://questionsmedicales.fr/article/38543119", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ph17030333" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines et peptides de signalisation intracellulaire", "item": "https://questionsmedicales.fr/mesh/D047908" }, { "@type": "ListItem", "position": 5, "name": "Protein-Serine-Threonine Kinases", "item": "https://questionsmedicales.fr/mesh/D017346" }, { "@type": "ListItem", "position": 6, "name": "Mitogen-Activated Protein Kinases", "item": "https://questionsmedicales.fr/mesh/D020928" }, { "@type": "ListItem", "position": 7, "name": "Extracellular Signal-Regulated MAP Kinases", "item": "https://questionsmedicales.fr/mesh/D048049" }, { "@type": "ListItem", "position": 8, "name": "Mitogen-Activated Protein Kinase 3", "item": "https://questionsmedicales.fr/mesh/D048052" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Mitogen-Activated Protein Kinase 3 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Mitogen-Activated Protein Kinase 3", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-18", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Mitogen-Activated Protein Kinase 3", "description": "Comment diagnostiquer une dysfonction de MAPK3 ?\nQuels tests sont utilisés pour évaluer MAPK3 ?\nY a-t-il des biomarqueurs associés à MAPK3 ?\nMAPK3 est-elle impliquée dans des maladies spécifiques ?\nQuels symptômes peuvent indiquer un problème avec MAPK3 ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Terminal+Repeat+Sequences&page=998#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Mitogen-Activated Protein Kinase 3", "description": "Quels symptômes sont liés à une activation excessive de MAPK3 ?\nMAPK3 affecte-t-elle le système immunitaire ?\nQuels signes cliniques sont associés à MAPK3 ?\nY a-t-il des symptômes neurologiques liés à MAPK3 ?\nComment la MAPK3 influence-t-elle le stress cellulaire ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Terminal+Repeat+Sequences&page=998#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Mitogen-Activated Protein Kinase 3", "description": "Comment prévenir les dysfonctionnements de MAPK3 ?\nY a-t-il des habitudes à éviter pour MAPK3 ?\nLe stress peut-il affecter MAPK3 ?\nDes exercices spécifiques aident-ils MAPK3 ?\nLa gestion du poids influence-t-elle MAPK3 ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Terminal+Repeat+Sequences&page=998#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Mitogen-Activated Protein Kinase 3", "description": "Quels traitements ciblent MAPK3 ?\nLa thérapie génique peut-elle corriger MAPK3 ?\nQuels médicaments affectent la voie MAPK3 ?\nY a-t-il des traitements naturels pour MAPK3 ?\nComment la nutrition influence-t-elle MAPK3 ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Terminal+Repeat+Sequences&page=998#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Mitogen-Activated Protein Kinase 3", "description": "Quelles complications peuvent survenir avec une dysfonction de MAPK3 ?\nMAPK3 est-elle liée à des maladies auto-immunes ?\nComment MAPK3 affecte-t-elle le cancer ?\nY a-t-il des risques cardiovasculaires liés à MAPK3 ?\nMAPK3 peut-elle influencer le vieillissement ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Terminal+Repeat+Sequences&page=998#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Mitogen-Activated Protein Kinase 3", "description": "Quels facteurs de risque sont associés à MAPK3 ?\nL'âge influence-t-il l'activité de MAPK3 ?\nY a-t-il des prédispositions génétiques pour MAPK3 ?\nLe mode de vie influence-t-il MAPK3 ?\nDes infections peuvent-elles affecter MAPK3 ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Terminal+Repeat+Sequences&page=998#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction de MAPK3 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de signalisation cellulaire peuvent être utilisés." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer MAPK3 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests de phosphorylation et les analyses protéomiques sont courants." } }, { "@type": "Question", "name": "Y a-t-il des biomarqueurs associés à MAPK3 ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux anormaux de certaines protéines peuvent indiquer une dysfonction de MAPK3." } }, { "@type": "Question", "name": "MAPK3 est-elle impliquée dans des maladies spécifiques ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est liée à des cancers et des maladies inflammatoires." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec MAPK3 ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes variés selon la maladie, comme la fatigue ou des douleurs chroniques." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une activation excessive de MAPK3 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Une activation excessive peut entraîner une inflammation et des douleurs." } }, { "@type": "Question", "name": "MAPK3 affecte-t-elle le système immunitaire ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle joue un rôle dans la régulation de la réponse immunitaire." } }, { "@type": "Question", "name": "Quels signes cliniques sont associés à MAPK3 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des éruptions cutanées ou des troubles métaboliques peuvent apparaître." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques liés à MAPK3 ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles neurologiques peuvent survenir en cas de dysfonction de MAPK3." } }, { "@type": "Question", "name": "Comment la MAPK3 influence-t-elle le stress cellulaire ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Elle régule les réponses au stress, affectant la survie cellulaire et l'apoptose." } }, { "@type": "Question", "name": "Comment prévenir les dysfonctionnements de MAPK3 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant une bonne nutrition et de l'exercice, est recommandé." } }, { "@type": "Question", "name": "Y a-t-il des habitudes à éviter pour MAPK3 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Éviter le tabagisme et une alimentation riche en graisses saturées est conseillé." } }, { "@type": "Question", "name": "Le stress peut-il affecter MAPK3 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut perturber la signalisation de MAPK3." } }, { "@type": "Question", "name": "Des exercices spécifiques aident-ils MAPK3 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des exercices réguliers peuvent améliorer la régulation de MAPK3." } }, { "@type": "Question", "name": "La gestion du poids influence-t-elle MAPK3 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Maintenir un poids santé peut aider à réguler l'activité de MAPK3." } }, { "@type": "Question", "name": "Quels traitements ciblent MAPK3 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs spécifiques de MAPK3 sont en développement pour traiter certains cancers." } }, { "@type": "Question", "name": "La thérapie génique peut-elle corriger MAPK3 ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est une approche potentielle pour corriger des mutations de MAPK3." } }, { "@type": "Question", "name": "Quels médicaments affectent la voie MAPK3 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme les inhibiteurs de MEK peuvent moduler l'activité de MAPK3." } }, { "@type": "Question", "name": "Y a-t-il des traitements naturels pour MAPK3 ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Certaines plantes médicinales peuvent influencer la signalisation de MAPK3." } }, { "@type": "Question", "name": "Comment la nutrition influence-t-elle MAPK3 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en antioxydants peut moduler l'activité de MAPK3." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec une dysfonction de MAPK3 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme le cancer, l'inflammation chronique et des troubles métaboliques peuvent survenir." } }, { "@type": "Question", "name": "MAPK3 est-elle liée à des maladies auto-immunes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies dans MAPK3 peuvent contribuer à des maladies auto-immunes." } }, { "@type": "Question", "name": "Comment MAPK3 affecte-t-elle le cancer ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une activation aberrante de MAPK3 est souvent observée dans divers types de cancer." } }, { "@type": "Question", "name": "Y a-t-il des risques cardiovasculaires liés à MAPK3 ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un lien entre MAPK3 et des maladies cardiovasculaires." } }, { "@type": "Question", "name": "MAPK3 peut-elle influencer le vieillissement ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des dysfonctionnements de MAPK3 sont associés à des processus de vieillissement prématuré." } }, { "@type": "Question", "name": "Quels facteurs de risque sont associés à MAPK3 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme l'obésité, le tabagisme et le stress sont des risques connus." } }, { "@type": "Question", "name": "L'âge influence-t-il l'activité de MAPK3 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'activité de MAPK3 peut diminuer avec l'âge, affectant la signalisation cellulaire." } }, { "@type": "Question", "name": "Y a-t-il des prédispositions génétiques pour MAPK3 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines mutations génétiques peuvent prédisposer à des dysfonctionnements de MAPK3." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il MAPK3 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent les risques." } }, { "@type": "Question", "name": "Des infections peuvent-elles affecter MAPK3 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections virales peuvent perturber la signalisation de MAPK3." } } ] } ] }

Sources (10000 au total)

Perinatal outcomes between immediate vs deferred selective termination in dichorionic twin pregnancies with fetal congenital anomalies: a French multicenter study.

Because selective termination (ST) for discordant dichorionic twin anomalies carries a risk of pregnancy loss, deferring the procedure until the third trimester can be considered in settings where it ... To determine whether perinatal outcomes were more favorable following deferred rather than immediate ST.... A French multicenter retrospective study from 2012 to 2023 on dichorionic twin pregnancies with ST for fetal conditions which were diagnosed before 24 WG. Pregnancies with additional risk factors for ... Of 390 pregnancies, 258 were in the immediate ST group and 132 in deferred ST group. Baseline characteristics were similar in both groups. Overall survival of the healthy co-twin was 93.8% (242/258) i... Overall survival after ST was high regardless of the gestational age at which the procedure was performed. Postponing ST until the third trimester seems to improve survival, while immediate ST reduces...

Correlation of cerebral microvascular circulation with vital signs in cerebral compression and the validity of three concepts: vasodilation, autoregulation, and terminal rise in arterial pressure.

Vasodilation, autoregulation, and rising arterial pressure are three common concepts in cerebral compression, believed to improve cerebral blood flow to maintain the brain's nutrition. However, these ... Without new animal experiments, a large amount of data: recording of vital signs, long movies of cerebral circulation, and numerous photos of histological examination and microvessels obstruction in c... As cerebral compression increased intracranial pressure (ICP), veins dilated, not arteries, and arterial microvessels obstructed, diminished, and stopped cerebral circulation. Simultaneously, vital si... In cerebral compression, rising ICP obstructs cerebral arterial microvessels while simultaneously deteriorating vital signs. There is no evidence for dilatation of the arteries; only veins dilate, bes...

Durable response from fibroblast growth factor receptor inhibition in intrahepatic cholangiocarcinoma terminated by metachronous acute myeloid leukemia: a case report.

Advances in the treatment of biliary tract cancer have been made possible through gains in genomic and epigenetic tumor understanding. The use of fibroblast growth factor receptor inhibitor has enable... We present the case of a 69-year-old Caucasian patient with advanced intrahepatic cholangiocarcinoma who received the therapy with selective oral inhibitor of fibroblast growth factor receptor 1, 2, a... It is still possible to achieve durable tumor response in advanced previously treated intrahepatic cholangiocarcinoma through targeted therapies. The prolonged progression free survival means that the...

Tyrosinase inhibitory peptides: Structure-activity relationship study on peptide chemical properties, terminal preferences and intracellular regulation of melanogenesis signaling pathways.

Bioactive peptides have gained attention as potential alternatives to chemical-based skin lightening agents. Based on literature search, the reported articles focused mainly on the sources and prepara... In this study, the sequences of 128 tyrosinase inhibitory peptides were collected from peer-reviewed articles. The hydrophobicity/hydrophilicity property and the amino acid profile of peptides at the ... It was found that hydrophobic and/or polar neutral properties may facilitate or stabilize peptide binding with tyrosinase. Moreover, short peptides featuring a cysteine and tyrosine at the N- and C- t... These findings provide detailed explanation on how peptide/amino acid structures are related and what function they play in tyrosinase inhibition. It could also inspire researchers to account for tyro...

Serum hyaluronic acid and procollagen III, N-terminal propeptide levels are highly associated with disease severity and predict the progression of COVID-19.

The coronavirus disease 2019 (COVID-19) pandemic is a rapidly evolving global emergency and continuously poses a serious threat to public health, highlighting the urgent need of identifying biomarkers... A total of 420 confirmed COVID-19 patients were included in the study. According to the "Diagnosis and Treatment of novel coronavirus Pneumonia (10th Edition)", the cases were divided into mild group ... Male patients over 46 years who have smoking habits were more likely to suffer from severe COVID-19. Critically ill patients had lower lymphocyte counts and red blood cell counts, and higher white blo... HA and PIIIN-P are highly associated with disease severity and progression of COVID-19 and can be used as new markers for the prediction of severe COVID-19....